{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:02Z","timestamp":1786980842568,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10557-024-07604-x","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T08:01:50Z","timestamp":1719993710000},"page":"849-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?"],"prefix":"10.1007","volume":"39","author":[{"given":"Carlos A.","family":"Gongora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Lopez","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Ruiz-Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Gonzalez-Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joffre","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cossio-Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-8771","authenticated-orcid":false,"given":"Juan","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"issue":"5","key":"7604_CR1","first-page":"363","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363\u201385.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"7604_CR2","first-page":"539","volume":"2","author":"S Bhatia","year":"2020","unstructured":"Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC: CardioOncology. 2020;2(4):539\u201352.","journal-title":"JACC: CardioOncology"},{"issue":"7","key":"7604_CR3","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3390\/biomedicines11071867","volume":"11","author":"D Basak","year":"2023","unstructured":"Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867.","journal-title":"Biomedicines."},{"issue":"1","key":"7604_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12672-023-00719-x","volume":"14","author":"W Wu","year":"2023","unstructured":"Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discov Oncol. 2023;14(1):127.","journal-title":"Discov Oncol"},{"issue":"3","key":"7604_CR5","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","volume":"16","author":"SH Armenian","year":"2015","unstructured":"Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123\u201336.","journal-title":"Lancet Oncol"},{"issue":"41","key":"7604_CR6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"3","key":"7604_CR7","first-page":"292","volume":"5","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Rankin S, Lang NN. Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity. JACC: CardioOncology. 2023;5(3):292\u20137.","journal-title":"JACC: CardioOncology"},{"issue":"20","key":"7604_CR8","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"H-M Chang","year":"2017","unstructured":"Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017;70(20):2536\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"7604_CR9","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"H-M Chang","year":"2017","unstructured":"Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"7604_CR10","first-page":"292","volume":"5","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Rankin S, Lang NN. Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology. 2023;5(3):292\u20137.","journal-title":"JACC: CardioOncology"},{"issue":"11","key":"7604_CR11","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342.","journal-title":"Nat Med"},{"issue":"11","key":"7604_CR12","doi-asserted-by":"publisher","first-page":"e008209","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","volume":"14","author":"E Jirkovsk\u00fd","year":"2021","unstructured":"Jirkovsk\u00fd E, Jirkovsk\u00e1 A, Bavlovi\u010d-Pisk\u00e1\u010dkov\u00e1 H, et al. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14(11):e008209.","journal-title":"Circ Heart Fail"},{"issue":"16","key":"7604_CR13","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","volume":"80","author":"LA Baldassarre","year":"2022","unstructured":"Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(16):1560\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"7604_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"7604_CR15","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2020.12.065","volume":"77","author":"SR Yurista","year":"2021","unstructured":"Yurista SR, Chong C-R, Badimon JJ, et al. Therapeutic potential of ketone bodies for patients with cardiovascular disease. J Am Coll Cardiol. 2021;77(13):1660\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"7604_CR16","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"MS Usman","year":"2023","unstructured":"Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377\u201387.","journal-title":"J Am Coll Cardiol"},{"key":"7604_CR17","doi-asserted-by":"publisher","unstructured":"Dutka M, Bobi\u0144ski R, Francuz T, et al. SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (Basel). 2022;14(23).\u00a0https:\/\/doi.org\/10.3390\/cancers14235811.","DOI":"10.3390\/cancers14235811"},{"issue":"1","key":"7604_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","volume":"19","author":"J Sabatino","year":"2020","unstructured":"Sabatino J, De Rosa S, Tamm\u00e8 L, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66.","journal-title":"Cardiovasc Diabetol"},{"key":"7604_CR19","doi-asserted-by":"publisher","first-page":"107171","DOI":"10.1016\/j.vph.2023.107171","volume":"150","author":"A Faggiano","year":"2023","unstructured":"Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S. SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: a systematic-review and meta-analysis. Vasc Pharmacol. 2023;150:107171.","journal-title":"Vasc Pharmacol"},{"issue":"12","key":"7604_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","volume":"49","author":"CM Oh","year":"2019","unstructured":"Oh CM, Cho S, Jang JY, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J. 2019;49(12):1183\u201395.","journal-title":"Korean Circ J"},{"issue":"9","key":"7604_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12012-021-09665-y","volume":"21","author":"V\u00d6 Bar\u0131\u015f","year":"2021","unstructured":"Bar\u0131\u015f V\u00d6, Din\u00e7soy AB, Gedikli E, et al. Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways. Cardiovasc Toxicol. 2021;21(9):747\u201358.","journal-title":"Cardiovasc Toxicol"},{"key":"7604_CR22","doi-asserted-by":"publisher","unstructured":"Quagliariello V, De Laurentiis M, Rea D, et al. SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, Leukotrienes\/Interleukin 6 axis and mTORC1 \/Fox01\/3a mediated apoptosis. Eur Heart J. 2020;41(Supplement_2).\u00a0https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3253.","DOI":"10.1093\/ehjci\/ehaa946.3253"},{"issue":"30","key":"7604_CR23","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci. 2015;112(30):E4111\u2013E9.","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"7604_CR24","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"7604_CR25","doi-asserted-by":"publisher","unstructured":"Giangiacomi F, Faggiano A, Cardinale D, et al. Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction\u2014a case series. Front Cardiovasc Med. 2023;10.\u00a0https:\/\/doi.org\/10.3389\/fcvm.2023.1250185.","DOI":"10.3389\/fcvm.2023.1250185"},{"issue":"8","key":"7604_CR26","first-page":"559","volume":"10","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, Drobni ZD, Silva TQAC, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC: Heart Failure. 2022;10(8):559\u201367.","journal-title":"JACC: Heart Failure"},{"issue":"1","key":"7604_CR27","doi-asserted-by":"publisher","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","volume":"8","author":"AP McGovern","year":"2020","unstructured":"McGovern AP, Hogg M, Shields BM, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"7604_CR28","first-page":"318","volume":"5","author":"H Abdel-Qadir","year":"2023","unstructured":"Abdel-Qadir H, Carrasco R, Austin PC, et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC: CardioOncology. 2023;5(3):318\u201328.","journal-title":"JACC: CardioOncology"},{"issue":"6","key":"7604_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","volume":"109","author":"C-H Chiang","year":"2023","unstructured":"Chiang C-H, Chiang C-H, Chiang C-H, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023;109(6):470\u20137.","journal-title":"Heart."},{"issue":"1","key":"7604_CR30","first-page":"67","volume":"12","author":"V Avula","year":"2024","unstructured":"Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy\u2013related cardiac dysfunction. JACC: Heart Failure. 2024;12(1):67\u201378.","journal-title":"JACC: Heart Failure"},{"issue":"1","key":"7604_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40959-023-00199-6","volume":"10","author":"MG Perelman","year":"2024","unstructured":"Perelman MG, Brzezinski RY, Waissengrin B, et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardio-Oncology. 2024;10(1):2.","journal-title":"Cardio-Oncology."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07604-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T21:11:32Z","timestamp":1757106692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07604-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7604"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07604-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"22 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"LS has received institutional grants from Amgen and Philips. The other authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}